Sever Pharma Solutions expands partnership with Silo Pharma

Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for high potent drugs, today announced an expanded agreement with Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. Under the new agreement, Sever Pharma Solutions will scale up extrusion processes and continue analytical testing for Silo’s investigational SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia.

Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for high potent drugs, today announced an expanded agreement with Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. Under the new agreement, Sever Pharma Solutions will scale up extrusion processes and continue analytical testing for Silo’s investigational SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia.

Sever Pharma Solutions has previously supported Silo in earlier development stages of the ketamine implants and successfully validated the delivery system through extensive long-term in-vitro release testing and drug product characterization. The expanded collaboration will enable further pre-clinical development of SP-26, focusing on refining time-released, dose-controlled formulations essential for the implant’s therapeutic efficacy and safety profile.

“We are pleased to continue our collaboration with Sever Pharma Solutions as we move forward with further pre-clinical testing of our novel non-opioid chronic pain therapeutic”, says Silo Pharma’s CEO Eric Weisblum. 

“This project together with Silo Pharma exemplifies our commitment to leveraging our specialized capabilities in polymer-based drug delivery systems to help bring novel, non-opioid treatment options closer to patients in need”, says Tony Listro, VP, Technology and Site Lead of Sever Pharma Solutions’ Putnam, CT USA facility.

SP-26 is designed as an injectable, dissolvable subcutaneous implant that delivers controlled doses of ketamine hydrochloride over time, potentially offering a safer and more consistent alternative for managing chronic pain. If clinically successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.